Japan’s TransGenic Dropping Knockout Mice For Antibodies
This article was originally published in PharmAsia News
Executive SummaryInstead of its usual practice of concentrating on creating mice with specific genetic defects, Japan's TransGenic is changing to focus more on diagnostics and reagent antibodies. The firm has decided "knockout mice" are too expensive to develop when new technologies are available so it has switched gears and plans instead to focus on licensing marketing rights for its antibodies. Prospective buyers would be makers of diagnostic drugs and reagents. Transgenic's plan is to make its antibody business a greater sales producer than its knockout mice. (Click here for more - a subscription may be required
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.